Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Medical Meeting
Dermabase.it
Reumabase.it

Search results for "Xeljanz"

The aim of a study was to describe the long-term safety and efficacy profile of Tofacitinib ( Xeljanz ) in patients with moderate to severe active rheumatoid arthritis. Data were pooled from 2 open ...


Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients. Researchers have investigated t ...


Tofacitinib ( Xeljanz ) is an oral Janus kinase ( JAK ) inhibitor for the treatment of rheumatoid arthritis ( RA ). Phase 2, phase 3, and open-label long-term extension ( LTE ) studies have described ...


Two-year results from the ORAL Start study were published in The New England Journal of Medicine ( NEJM ). ORAL Start is a 24-month phase 3 study in patients with moderately to severely active rheumat ...


A study aimed to assess the relative efficacy and safety of biologics and Tofacitinib ( Xeljanz ) in patients with rheumatoid arthritis showing an inadequate response to tumor necrosis factor ( TNF ) ...